In-Utero Endoscopic Correction of Spina Bifida

Last updated: March 24, 2025
Sponsor: University of Southern California
Overall Status: Active - Recruiting

Phase

N/A

Condition

Holoprosencephaly

Treatment

In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique

In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique

Clinical Study ID

NCT04362592
HS-05-00374
  • Ages 18-52
  • Female
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate the feasibility and effectiveness of performing fetoscopic surgical correction of fetal spina bifida. Two surgical approaches will be utilized: the percutaneous technique versus the laparotomy/uterine exteriorization technique.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Myelomeningocele (including myeloschisis) at level T1 through S1 with hindbrainherniation. Lesion level and hindbrain herniation will be confirmed by MRI andultrasonography.

  2. Maternal age ≥18 years.

  3. Gestational age of 19 to 27 6/7 weeks' gestation as determined by clinicalinformation and evaluation of first ultrasound.

  4. Balanced karyotype and/or normal mircoarray with written confirmation of cultureresults. Results by fluorescence in situ hybridization (FISH) will be acceptable ifthe patient is at 24 weeks or more.

  5. Positive evaluation of social work consult indicating the patient is capable ofconsenting to the procedure and has the appropriate social support system toparticipate in the study.

  6. Positive evaluation from pediatric neurology consult.

  7. Willing to return to our center, or to a multi-disciplinary spina bifida cliniccloser to their home for the 6, 12, 24, 30, 48, and 60 months follow-up evaluations.

Exclusion

Exclusion Criteria:

  1. Multiple gestation

  2. Insulin-dependent pregestational diabetes

  3. Presence of a fetal anomaly not related to Chiari II Malformation. A fetalechocardiogram will be conducted before surgery and if the finding is abnormal, thepatient will be excluded.

  4. Fetal kyphosis of 30 degrees or more, assessed by ultrasound or MRI.

  5. Presence of uterine cervical cerclage or history of incompetent cervix.

  6. Placenta previa or placental abruption.

  7. Short cervix < 25 mm measured by cervical ultrasound.

  8. Obesity as defined by body mass index (BMI) of 40 or greater.

  9. History of previous spontaneous singleton delivery prior to 37 weeks.

  10. Maternal-fetal Rh isoimmunization, Kell sensitization or a history of neonatalalloimmune thrombocytopenia.

  11. Maternal HIV or Hepatitis-B status positive because of the increased risk oftransmission to the fetus during maternal-fetal surgery. If the patient's HIV orHepatitis B status is unknown, the patient must be tested and found to have negativeresults before she can be enrolled.

  12. Known Hepatitis-C positivity. If the patient's Hepatitis C status is unknown, shedoes not need to be screened.

  13. Uterine anomaly such as large (greater than 6 cm) fibroids, cervical fibroids ormultiple fibroids or Mullerian duct abnormality.

  14. Other maternal medical condition which is a contraindication to surgery oranesthesia.

  15. Patient does not have a support person (e.g., husband, partner, parents).

  16. Inability to comply with the travel and follow-up requirements of the study.

  17. Patient does not meet psychosocial criteria as determined by the social workerevaluation.

  18. Participation in another intervention study that influences maternal and fetalmorbidity and mortality.

  19. Maternal hypertension as determined by the investigator, which would increase therisk of preeclampsia or preterm delivery (including, but not limited to:uncontrolled hypertension, chronic hypertension with end organ damage and new onsethypertension in current pregnancy).

  20. Bicornuate uterus or any other uterine malformation the PI decides is not safe forsurgery.

  21. Nickel allergy.

  22. Maternal request to undergo open fetal surgery for the antenatal correction of OSBat our institution primarily or after failed fetoscopic approach.

  23. Known maternal hypersensitivity to bovine collagen or chondroitin materials.

Study Design

Total Participants: 110
Treatment Group(s): 2
Primary Treatment: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique
Phase:
Study Start date:
November 02, 2018
Estimated Completion Date:
October 31, 2031

Connect with a study center

  • Hollywood Presbyterian Medical Center

    Los Angeles, California 90027
    United States

    Active - Recruiting

  • Huntington Hospital

    Pasadena, California 91105
    United States

    Site Not Available

  • Wellington Regional Medical Center

    Wellington, Florida 33141
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.